The Mayo Endoscopic Score Is a Novel Predictive Indicator for Malignant Transformation in Ulcerative Colitis: A Long-Term Follow-Up Multicenter Study

Weimin Xu; Fangyuan Liu; Wenbo Tang; Yubei Gu; Jie Zhong; Long Cui; Peng Du

doi:10.3389/fsurg.2022.832219

The Mayo Endoscopic Score Is a Novel Predictive Indicator for Malignant Transformation in Ulcerative Colitis: A Long-Term Follow-Up Multicenter Study

Front Surg. 2022 Mar 16:9:832219. doi: 10.3389/fsurg.2022.832219. eCollection 2022.

Authors

Weimin Xu¹, Fangyuan Liu¹, Wenbo Tang¹, Yubei Gu², Jie Zhong², Long Cui¹, Peng Du¹

Affiliations

¹ Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
² Department of Gastroenterology, Rui Jin Hospital, Affiliate to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.

Abstract

Background: Data on the relative risk of malignant transformation in ulcerative colitis (UC) are insufficient. We investigated the potential value of the Mayo endoscopic score (MES) for predicting malignant transformation in patients with UC.

Methods: Data of patients with UC evaluated at our institute from June 1986 to December 2019 were retrospectively analyzed. The MES used in the study indicated the results of the first colonoscopy after hospitalization. We defined MES of 0-1 as low and MES of 2-3 as high. Univariable and multivariate logistic regression models were used for statistical analysis.

Results: Among the 280 eligible patients with UC with a median follow-up time of 14 (interquartile range, 10.0-18.0) years, those with a high MES were more likely to develop malignant transformation. High MES positively correlated with the degree of malignancy and was an independent risk factor for UC-associated dysplasia and colorectal cancer (CRC, odds ratio [OR], 9.223; 95% confidence interval [CI], 1.160-73.323; p = 0.036). Disease duration >5 years (OR, 2.05; 95% CI, 1.177-3.572; p = 0.011), immunomodulator use (OR, 4.314; 95% CI, 1.725-10.785; p = 0.002), biologics nonuse (OR, 3.901; 95%CI, 2.213-6.876; p < 0.001), and Hb <90 g/L (OR, 2.691; 95% CI, 1.251-5.785; p = 0.011) were contributing factors for high MES.

Conclusion: High MES could be a novel predictor of malignant transformation in UC. Clinicians should optimize the use of biologics and immunomodulators early and should actively correct anemia to improve the MES and then reduce the incidence of UC-associated dysplasia and CRC.

Keywords: Mayo endoscopic score; colitis; colorectal cancer; malignant transformation; ulcerative colitis.